Treatment with bimatoprost for exophthalmos in patients with inactive thyroid-associated ophthalmopathy

被引:2
|
作者
Higashiyama, Tomoaki [1 ]
Ohji, Masahito [1 ]
机构
[1] Shiga Univ Med Sci, Dept Ophthalmol, Tsukinowa Cho, Otsu, Shiga 5202192, Japan
来源
CLINICAL OPHTHALMOLOGY | 2018年 / 12卷
关键词
bimatoprost; thyroid-associated ophthalmopathy; exophthalmos; orbital fat;
D O I
10.2147/OPTH.S187164
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: This study was performed to observe changes prospectively in exophthalmos and orbital fat in patients with inactive thyroid-associated ophthalmopathy (TAO) treated with bimatoprost. Methods: In this 12-month single-treatment pilot observational study, 13 patients with inactive-phase TAO were administered bimatoprost to treat exophthalmos due to TAO. Exophthalmos values and orbital tissue volumes were measured on MRI by technicians in a masked fashion. Results: Nine orbits of nine patients (eight women, one man) were treated with bimatoprost for 12 months. Mean exophthalmos values before and after treatment were 21.7 +/- 2.2 and 21.7 +/- 2.0 mm, respectively. The mean value after 12 months of treatment was not significantly different from before treatment (P=0.82). Mean orbital fat volume before and after 12 months of treatment was 17.2 +/- 2.5 and 17.0 +/- 3.0 cm(3), respectively. The corresponding total extraocular muscle volume was 4.0 +/- 0.7 and 3.8 +/- 0.9 cm(3), respectively. Mean volume in each tissue type after 12 months of treatment was not significantly different from before treatment (orbital fat, P=0.70; extraocular muscles, P=0.32). Conclusion: Topical bimatoprost treatment did not reduce exophthalmos or orbital fat in this cohort of patients with inactive TAO.
引用
收藏
页码:2415 / 2421
页数:7
相关论文
共 50 条
  • [41] Current management of thyroid-associated ophthalmopathy
    Kendall-Taylor, P
    CLINICAL ENDOCRINOLOGY, 1998, 49 (01) : 11 - 12
  • [42] PATHOGENETIC MECHANISMS IN THYROID-ASSOCIATED OPHTHALMOPATHY
    PERROS, P
    KENDALLTAYLOR, P
    JOURNAL OF INTERNAL MEDICINE, 1992, 231 (03) : 205 - 211
  • [43] Teprotumumab for thyroid-associated ophthalmopathy OPTIC
    Gaertner, R.
    Nitschmann, S.
    INTERNIST, 2020, 61 (11): : 1208 - 1210
  • [44] Measurements of saccades in thyroid-associated ophthalmopathy
    Schworm, HD
    Buser, A
    Botzel, K
    Heufelder, AE
    Leikam, B
    Boergen, KP
    OPHTHALMOLOGE, 1997, 94 (03): : 211 - 216
  • [45] Optimal timing for cataract surgery in patients with thyroid-associated ophthalmopathy
    Miao, Na
    Chen, Yan-Chi
    He, Wei-Min
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2025, 18 (04) : 606 - 614
  • [46] Changes in extraocular muscle function in patients with thyroid-associated ophthalmopathy
    Schworm, HD
    Heufelder, AE
    Botzel, K
    Leikam, B
    Beicht, L
    Boergen, KP
    OPHTHALMOLOGE, 1997, 94 (04): : 290 - 294
  • [47] Identification of thyroglobulin in orbital tissues of patients with thyroid-associated ophthalmopathy
    Marinò, M
    Lisi, S
    Pinchera, A
    Mazzi, B
    Latrofa, F
    Sellari-Franceschini, S
    McCluskey, RT
    Chiovato, L
    THYROID, 2001, 11 (02) : 177 - 185
  • [48] Results of transantral orbital decompression in patients with thyroid-associated ophthalmopathy
    Tallstedt, L
    Papatziamos, G
    Lundblad, L
    Änggård, A
    ACTA OPHTHALMOLOGICA SCANDINAVICA, 2000, 78 (02): : 206 - 210
  • [49] Detection of active and inactive phases of thyroid-associated ophthalmopathy using deep convolutional neural network
    Lin, Chenyi
    Song, Xuefei
    Li, Lunhao
    Li, Yinwei
    Jiang, Mengda
    Sun, Rou
    Zhou, Huifang
    Fan, Xianqun
    BMC OPHTHALMOLOGY, 2021, 21 (01)
  • [50] Detection of active and inactive phases of thyroid-associated ophthalmopathy using deep convolutional neural network
    Chenyi Lin
    Xuefei Song
    Lunhao Li
    Yinwei Li
    Mengda Jiang
    Rou Sun
    Huifang Zhou
    Xianqun Fan
    BMC Ophthalmology, 21